142 related articles for article (PubMed ID: 37865044)
1. Clinical consequences of a genetic predisposition toward higher benign prostate-specific antigen levels.
Shi M; Shelley JP; Schaffer KR; Tosoian JJ; Bagheri M; Witte JS; Kachuri L; Mosley JD
EBioMedicine; 2023 Nov; 97():104838. PubMed ID: 37865044
[TBL] [Abstract][Full Text] [Related]
2. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.
Kader AK; Liss MA; Trottier G; Kim ST; Sun J; Zheng SL; Chadwick K; Lockwood G; Xu J; Fleshner NE
Urology; 2015 Jan; 85(1):165-70. PubMed ID: 25530379
[TBL] [Abstract][Full Text] [Related]
3. Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection.
Hughes L; Zhu F; Ross E; Gross L; Uzzo RG; Chen DY; Viterbo R; Rebbeck TR; Giri VN
Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):53-60. PubMed ID: 22144497
[TBL] [Abstract][Full Text] [Related]
4. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
5. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
[TBL] [Abstract][Full Text] [Related]
6. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
7. Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men.
Giri VN; Egleston B; Ruth K; Uzzo RG; Chen DY; Buyyounouski M; Raysor S; Hooker S; Torres JB; Ramike T; Mastalski K; Kim TY; Kittles R
Cancer Prev Res (Phila); 2009 Mar; 2(3):244-50. PubMed ID: 19240249
[TBL] [Abstract][Full Text] [Related]
8. Genetically adjusted PSA levels for prostate cancer screening.
Kachuri L; Hoffmann TJ; Jiang Y; Berndt SI; Shelley JP; Schaffer KR; Machiela MJ; Freedman ND; Huang WY; Li SA; Easterlin R; Goodman PJ; Till C; Thompson I; Lilja H; Van Den Eeden SK; Chanock SJ; Haiman CA; Conti DV; Klein RJ; Mosley JD; Graff RE; Witte JS
Nat Med; 2023 Jun; 29(6):1412-1423. PubMed ID: 37264206
[TBL] [Abstract][Full Text] [Related]
9. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
D'Amico AV; Renshaw AA; Sussman B; Chen MH
JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
[TBL] [Abstract][Full Text] [Related]
11. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
[TBL] [Abstract][Full Text] [Related]
12. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
Remmers S; Bangma CH; Godtman RA; Carlsson SV; Auvinen A; Tammela TLJ; Denis LJ; Nelen V; Villers A; Rebillard X; Kwiatkowski M; Recker F; Wyler S; Zappa M; Puliti D; Gorini G; Paez A; Lujan M; Nieboer D; Schröder FH; Roobol MJ
Eur Urol; 2023 Nov; 84(5):503-509. PubMed ID: 37088597
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.
Huynh-Le MP; Karunamuni R; Fan CC; Asona L; Thompson WK; Martinez ME; Eeles RA; Kote-Jarai Z; Muir KR; Lophatananon A; Schleutker J; Pashayan N; Batra J; Grönberg H; Neal DE; Nordestgaard BG; Tangen CM; MacInnis RJ; Wolk A; Albanes D; Haiman CA; Travis RC; Blot WJ; Stanford JL; Mucci LA; West CML; Nielsen SF; Kibel AS; Cussenot O; Berndt SI; Koutros S; Sørensen KD; Cybulski C; Grindedal EM; Menegaux F; Park JY; Ingles SA; Maier C; Hamilton RJ; Rosenstein BS; Lu YJ; Watya S; Vega A; Kogevinas M; Wiklund F; Penney KL; Huff CD; Teixeira MR; Multigner L; Leach RJ; Brenner H; John EM; Kaneva R; Logothetis CJ; Neuhausen SL; De Ruyck K; Ost P; Razack A; Newcomb LF; Fowke JH; Gamulin M; Abraham A; Claessens F; Castelao JE; Townsend PA; Crawford DC; Petrovics G; van Schaik RHN; Parent MÉ; Hu JJ; Zheng W; ; ; ; ; ; ; ; Mills IG; Andreassen OA; Dale AM; Seibert TM
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):755-761. PubMed ID: 35152271
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Mikropoulos C; Selkirk CGH; Saya S; Bancroft E; Vertosick E; Dadaev T; Brendler C; Page E; Dias A; Evans DG; Rothwell J; Maehle L; Axcrona K; Richardson K; Eccles D; Jensen T; Osther PJ; van Asperen CJ; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Hart R; Glover W; Lam J; Taylor L; Salinas M; Feliubadaló L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Cook J; Rosario DJ; Buys SS; Conner T; Domchek S; Powers J; Ausems MG; Teixeira MR; Maia S; Izatt L; Schmutzler R; Rhiem K; Foulkes WD; Boshari T; Davidson R; Ruijs M; Helderman-van den Enden AT; Andrews L; Walker L; Snape K; Henderson A; Jobson I; Lindeman GJ; Liljegren A; Harris M; Adank MA; Kirk J; Taylor A; Susman R; Chen-Shtoyerman R; Pachter N; Spigelman A; Side L; Zgajnar J; Mora J; Brewer C; Gadea N; Brady AF; Gallagher D; van Os T; Donaldson A; Stefansdottir V; Barwell J; James PA; Murphy D; Friedman E; Nicolai N; Greenhalgh L; Obeid E; Murthy V; Copakova L; McGrath J; Teo SH; Strom S; Kast K; Leongamornlert DA; Chamberlain A; Pope J; Newlin AC; Aaronson N; Ardern-Jones A; Bangma C; Castro E; Dearnaley D; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lubinski J; Grindedal EM; McKinley J; Shackleton K; Mitra AV; Moynihan C; Rennert G; Suri M; Tricker K; ; Moss S; Kote-Jarai Z; Vickers A; Lilja H; Helfand BT; Eeles RA
Br J Cancer; 2018 Jan; 118(2):266-276. PubMed ID: 29301143
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
17. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
18. A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies.
Nordström T; Bratt O; Örtegren J; Aly M; Adolfsson J; Grönberg H
Scand J Urol; 2016; 50(2):104-9. PubMed ID: 26625178
[TBL] [Abstract][Full Text] [Related]
19. Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.
Gilbert R; Martin RM; Evans DM; Tilling K; Davey Smith G; Kemp JP; Lane JA; Hamdy FC; Neal DE; Donovan JL; Metcalfe C
PLoS One; 2015; 10(10):e0136735. PubMed ID: 26431041
[TBL] [Abstract][Full Text] [Related]
20. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs.
Jiang H; Liu F; Wang Z; Na R; Zhang L; Wu Y; Zheng J; Lin X; Jiang D; Sun J; Zheng SL; Ding Q; Xu J
Prostate; 2013 Nov; 73(15):1651-9. PubMed ID: 23868750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
